Definitive Healthcare (DH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $62.7 million, down 4% year-over-year but exceeded guidance; adjusted EBITDA was $20.6 million (33% margin), down 5% year-over-year.

• Net loss was $187.8 million, driven by a $228.2 million goodwill impairment; adjusted net income was $15.4 million.

• Renewal rates improved modestly but remain below target, especially in life sciences; customer wins included notable win-backs and expansion in healthcare B2B and consumer markets.

• Strategic focus is on simplifying the product portfolio, moving to a unified platform, and investing in enterprise customer growth.

• Macroeconomic headwinds, sales execution challenges, and heightened customer churn, especially among smaller customers, continue to impact growth.

Financial highlights

• Subscription revenue decreased low single digits; professional services revenue declined more sharply; adjusted gross profit was $51.7 million (82% margin), down 8% year-over-year.

• Adjusted net income rose 6% to $15.4 million; adjusted EPS was $0.10; unlevered free cash flow was $24.3 million in Q3 and $85.2 million TTM, up 58% year-over-year.

• Ended Q3 with $305.4 million in cash and short-term investments; $247.5 million in debt; net leverage ratio below 0x.

• Net loss improved to $(187.8) million from $(248.7) million year-over-year, both periods impacted by goodwill impairments.

• Cash flow from operations was $19.4 million; net cash used in investing activities was $8.9 million.

Outlook and guidance

• Q4 2024 revenue expected at $60–$61 million, down 7–9% year-over-year; adjusted EBITDA $16–$17 million (26–28% margin); adjusted net income $10.5–$11.5 million.

• Full-year 2024 revenue guidance is $250.0–$251.0 million; adjusted EBITDA $77.5–$78.5 million; adjusted EPS $0.34–$0.35.

• 2025 revenue expected to be lower than 2024, with sequential growth targeted for the second half of 2025; adjusted EBITDA margin expected to contract by several hundred basis points.

• Guidance reflects a tightened revenue range, maintaining the high end of prior guidance.

• Current remaining performance obligations declined 4% year-over-year, signaling ongoing revenue pressure.